AzTrials
AzTrials

GallstoneML_vs_EHLNCT04970030

Comparison Between Mechanical Intracanal (ML) Lithotripsy and Electrohydraulic Intracolangioscopic (EHL) Lithotripsy in the Treatment of Difficult Main Biliary Tract Lithiasis

A study testing ML lithotripsy and EHL lithotripsy in people with Gallstone and Lithiasis, run by Azienda Usl di Bologna at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Difficult gallstones are found in about 10-15% of endoscopic retrograde cholangiopancreaticography (ERCP) performed for choledocholithiasis. There are several options for the treatment of difficult biliary lithiasis including mechanical lithotripsy and peroral cholangioscopy with electrohydraulic lithotripsy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Gallstone, Lithiasis
What is being tested?
ML lithotripsy and EHL lithotripsy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteItaly
Study dates
1 Jun 2021to 1 Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients with "difficult" biliary tract lithiasis that could not be treated by standard techniques, such as balloon and/or basket catheter under fluoroscopic vision.

Who cannot join

  • surgically-altered gastrointestinal anatomy
  • any evidence of biliopancreatic malignancy
  • patients under 18 years of age
  • patients in a state of pregnancy or are breastfeeding
  • no informed consent

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • Azienda USL di Bologna

    Bologna

    Vincenzo Cennamo, MD, +39 051 6478844, vincenzo.cennamo@ausl.bo.it

    Recruiting

Other trials in Italy

About this study

Difficult gallstones are found in about 10-15% of endoscopic retrograde cholangiopancreaticography (ERCP) performed for choledocholithiasis. There are several options for the treatment of difficult biliary lithiasis including mechanical lithotripsy and peroral cholangioscopy with electrohydraulic lithotripsy.

The primary purpose of this study is to compare the effectiveness of treating difficult biliary lithiasis with ML and with EHL. The effectiveness is defined by the complete cleanliness of the biliary tract in a single endoscopic session

Read the detailed description

Difficult gallstones are found in about 10-15% of endoscopic retrograde cholangiopancreaticography (ERCP) performed for choledocholithiasis. There are several options for the treatment of difficult biliary lithiasis including mechanical lithotripsy and peroral cholangioscopy with electrohydraulic lithotripsy.

The primary purpose of this study is to compare the effectiveness of treating difficult biliary lithiasis with ML and with EHL. The effectiveness is defined by the complete cleanliness of the biliary tract in a single endoscopic session.

The secondary objectives of the study are as follows:

  • Within 30 days of the procedure, the effective clearance of the biliary tract will be assessed with CholangioRM (or EUS where MRI is contraindicated). If residual choledocholithiasis is present, patients will be considered as late failures.
  • Comparison of the safety of the treatments under study, defined by the incidence of adverse events during the procedure (e.g. perforation, hemobilia) and in the observation period after the procedure (e.g. cholangitis, pancreatitis, bleeding).

Patients that can be enrolled:

All patients with "difficult" biliary tract lithiasis that could not be treated by standard techniques, such as balloon and/or basket catheter under fluoroscopic vision.

Patients cannot be enrolled:

  • if they have a surgically-altered gastrointestinal anatomy
  • if they have any evidence of biliopancreatic malignancy
  • if they are under 18 years of age
  • if they are in a state of pregnancy or are breastfeeding
  • if it's impossible to obtain informed consent

If, while performing ERCP for choledocholithiasis, stones are found that cannot be removed using standard treatment, they will be treated by assigning these patients to either the treatment group with ML under fluoroscopic vision or to the EHL treatment group.

Patients will be assigned using a randomization method in blocks with a ratio of 1:1 for each patient enrolled.

Subjects will undergo ERCP, either under general anesthesia, or under observation by an anesthesiologist, and depending on which group they have been assigned to, will be treated with:

  • EHL: after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
  • ML: we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.

During each procedure, the following will be recorded:

  • the execution time from the insertion of the cholangioscope or lithotripter inside the biliary tract until the complete cleaning of the biliary tract is finished.
  • the occurrence of possible adverse events related to the procedures and/or anesthetic issues.
  • any failure of a technique and / or the need to switch a patient to the other treatment group.

At least 50 patients eligible for the study will be required.

Conditions
Gallstone, Lithiasis
Being tested
ML lithotripsy, EHL lithotripsy
Keywords
Gallstone, Lithiasis, ML lithotripsy, EHL lithotripsy
Medical subject headings
Gallstones, Lithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ML lithotripsyProcedure or surgery

    we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.

  • EHL lithotripsyProcedure or surgery

    after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique

Study groups in NCT04970030
Study groupRoleWhat they receive
mechanical intracanal (ML) lithotripsyActive comparatorTTS mechanical lithotripter
Receives: Procedure: ML lithotripsy
electrohydraulic intracolangioscopic (EHL) lithotripsyExperimentalelectrohydraulic lithotripsy with Autolith probe
Receives: Procedure: EHL lithotripsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ML - EHL comparison

    The primary purpose of this study is to compare the effectiveness of treating difficult biliary lithiasis with ML and with EHL. The effectiveness is defined by the complete cleanliness of the biliary tract in a single endoscopic session

    Measured: 1 day

Secondary outcomes (2)
  1. effective clearance of the biliary tract

    Within 30 days of the procedure, the effective clearance of the biliary tract will be assessed with CholangioRM (or EUS where MRI is contraindicated). If residual choledocholithiasis is present, patients will be considered as late failures.

    Measured: 30 days

  2. Comparison of the safety of the treatments under study

    Comparison of the safety of the treatments under study, defined by the incidence of adverse events during the procedure (e.g. perforation, hemobilia) and in the observation period after the procedure (e.g. cholangitis, pancreatitis, bleeding).

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2021
  2. Study start1 Jun 2021
  3. Primary completion1 Jul 2023 (estimated)
  4. Study completion1 Aug 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04970030
Sponsor's protocol ID
397-2021-SPER-AUSLBO
Acronym
ML_vs_EHL
Status last verified
Jul 2021
First submitted
16 Jul 2021
Last updated
21 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ML lithotripsy and EHL lithotripsy in people with Gallstone and Lithiasis, run by Azienda Usl di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Vincenzo Cennamo, Md (+39 051 6478844, vincenzo.cennamo@ausl.bo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ML - EHL comparison (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in